Merck & Co Inc
(TSX:MRK)
C$
28.29
-0.030 (-0.11%)
Market Cap: 441.77 Bil
Enterprise Value: 503.48 Bil
PE Ratio: 35.49
PB Ratio: 6.78
GF Score: 64/100 Merck & Co Inc at Citi Global Healthcare Conference Transcript
Dec 03, 2025 / 06:00PM GMT
Release Date Price:
C$23.18
(+0.91%)
Geoffrey Meacham;Douala Branch;Analyst
Citibank Cameroon SA
()-
Second day of the Citi Global Healthcare Conference. So my name is Geoff Meacham. I'm the senior biopharma analyst of Mary-Kate Davis with me as well from my team here on stage. So we're thrilled to have Merck in this session, and we have Eliav Barr, who was SVP Head of Global Clinical Development and CMO; and then Chirfi Guindo, Chief Marketing Officer. So Eliav, good to see you guys.
Eliav Barr
Merck & Co Inc - SVP Head of Global Clinical Development and CMO
So here as well. Thank you for having us.
Questions & Answers
Geoffrey Meacham;Douala Branch;Analyst
Citibank Cameroon SA
()-
Thanks for the time. So maybe we'll start with the -- first, with the Cidara deal, right? So maybe just give us some kind of context for the thought process that went into this. I mean I'm assuming it's more than just kind of economics and to try to manage the LOE. This is a real growth
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |

30-Day 100% money back guarantee
Subscription fee may be tax deductible.
Excellent 

4.6 out of 5
Trustpilot